Join the club for FREE to access the whole archive and other member benefits.

Immunai, to map immune system for better diagnosis, disease treatment

14-May-2020

Key points from article :

Immunai claims its platform can be used to more accurately monitor efficacy of immunotherapy.

"Our platform identifies common patterns not visible looking at narrower disease-specific view."

Uses single-cell technologies to extract data from blood samples.

Then uses machine learning algorithms to map data to cell types and create immune profiles.

The database of immune profiles supports biomarker discovery and insight generation.

This identifies subtle changes in cell type and state-specific expression.

GE Healthcare partnered with Vanderbilt University Medical Center last year.

This is to use AI to retroactively analyze data from anonymized patient records.

Creates new tools allowing clinicians to more accurately predict patients' response to therapy.

National University of Singapore unveiled a cancer "scorecard" or Tumor Matrisome Index.

Developed using big data, predictive analysis of more than 30,000 patient-derived biopsies.

This application of machine learning will soon speed up drug development

Mentioned in this article:

Company
Immunai
- Biotech company, New York
Academic
Jeff Balser
- President and CEO of Vanderbilt University Medical Center
Company Representative
Luis Voloch
- Chief echnology Officer and Co-founder, Immunai
Academia
National University of Singapore (NUS)
- Asia’s leading university with a global approach in education, research and service.
Company Representative
Noam Solomon
- CEO and Co-founder, Immunai
Institute
Vanderbilt University Medical Center
- Hospital and health care center.